First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at
New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration
Third quarter financings increased cash and cash equivalents to
Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added: “During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to
Recent Milestones & Business Highlights
First Patient Dosed in Phase 2/3 Clinical Trial of SIL204: On
Clinical Site Expansion in
Expanded Translational Profile of SIL204: In
Financing Activities: During the third quarter, Silexion completed a registered public offering in
Financial Results for the Three Months Ended
Research and development (“R&D”) expenses for the three months ended
General and administrative (“G&A”) expenses for the three months ended
Net loss for the three months ended
Financial Results for the Nine Months Ended
R&D expenses for the nine months ended
G&A expenses for the nine months ended
Net loss for the nine months ended
Balance Sheet Highlights
- As of
September 30, 2026 , Silexion had cash and cash equivalents of$4.8 million , compared to$6.0 million as ofDecember 31, 2025 , and$2.2 million as ofJune 30, 2026 . - Total shareholders’ equity was
$3.0 million as ofSeptember 30, 2026 , compared to$2.6 million as ofDecember 31, 2025 .
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication are forward-looking statements, including, for example, statements regarding the development of SIL204; the conduct, enrollment and timing of the ongoing Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, including enrollment of the safety run-in cohort and expansion into a randomized cohort; the timing of activation of additional clinical trial sites in Israel and Germany and the potential expansion of the trial into additional jurisdictions; the timing and results of ongoing translational, pharmacokinetic, cellular uptake and biodistribution studies, and the potential to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies; the potential therapeutic benefits, mutation coverage, mechanism of action and clinical utility of SIL204 across KRAS-driven cancers; Silexion’s business strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements, including through its at-the-market facility, public and private offerings, warrant exercises, warrant inducement transactions and other financing arrangements; the outcome of litigation; and Silexion’s ability to restore and maintain compliance with Nasdaq continued listing requirements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial of SIL204, and the risk that early observations may not be predictive of later results; (ii) Silexion’s ability to enroll and treat patients, and to complete the activation of additional clinical sites, on anticipated timelines; (iii) whether Silexion is able to successfully execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iv) the impact of the regulatory environment and compliance complexities; (v) whether Silexion is able to develop future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s operations of any inability to secure such capital; (vii) the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(e) to the Company’s unaudited condensed consolidated financial statements for the three-month and nine-month periods ended September 30, 2026; (viii) whether Silexion succeeds at maintaining its Nasdaq listing, including the determination of the Nasdaq hearings panel, compliance with the shareholders’ equity and minimum bid price requirements, and any potential increase to the market value of listed securities requirement; and (ix) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com
Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and per share data)
| 2026 | 2025 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | ||
| Restricted cash | 28 | 27 |
| Prepaid expenses | 1,221 | 570 |
| Other current assets | 102 | 49 |
| TOTAL CURRENT ASSETS | 6,111 | 6,637 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | 61 | 57 |
| Long-term deposit and other non-current assets | 320 | 84 |
| Property and equipment, net | 21 | 25 |
| Operating lease right-of-use asset | 314 | 412 |
| TOTAL NON-CURRENT ASSETS | 716 | 578 |
| TOTAL ASSETS |
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (continued)
(
| 2026 | 2025 | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Trade payables | ||
| Current maturities of operating lease liability | 196 | 182 |
| Employee related obligations | 460 | 879 |
| Other account payable | 1,781 | 910 |
| Private warrants to purchase ordinary shares (including $* due to related party, as of | * | * |
| TOTAL CURRENT LIABILITIES | 3,681 | 2,758 |
| NON-CURRENT LIABILITIES: | ||
| Long-term operating lease liability | 178 | 286 |
| Related Party Promissory Note | - | 1,568 |
| TOTAL NON-CURRENT LIABILITIES | ||
| TOTAL LIABILITIES | ||
| SHAREHOLDERS’ EQUITY: | ||
| Ordinary shares ( | 1,954 | 42 |
| Additional paid-in capital | 64,997 | 57,727 |
| Accumulated deficit | (63,983) | (55,166) |
| TOTAL SHAREHOLDERS’ EQUITY | ||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
All share amounts, and par value per share, reflect a 1-for-10 reverse share split effected on
* Represents an amount less than
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(
| Nine months ended | Three months ended | |||
| 2026 | 2025 | 2026 | 2025 | |
| OPERATING EXPENSES: | ||||
| Research and development (including | ||||
| General and administrative (including | 4,245 | 3,461 | 1,398 | 1,135 |
| TOTAL OPERATING EXPENSES | 9,113 | 7,226 | 2,684 | 3,292 |
| OPERATING LOSS | 9,113 | 7,226 | 2,684 | 3,292 |
| Financial expenses (income), net (including | (296) | 271 | (151) | (30) |
| LOSS BEFORE INCOME TAX | ||||
| INCOME TAX | * | 3 | * | - |
| NET LOSS | ||||
| LOSS PER SHARE, BASIC AND DILUTED | ||||
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE** | 76,305 | 3,017 | 184,927 | 4,720 |
* Represents an amount less than
** All share and per share amounts reflect (for periods preceding the relevant reverse share split, on a retroactive basis) the 1-for-10 reverse share split effected on
Source: 